$27.98
+1.71%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
Key dataAug 12, 2026
Open$28.33
From 52W high−25.62%
Volume375197.00
Market cap$1.84B
P/E (TTM)3.3x
P/S (TTM)1.5x
Div yield—
Key dataAug 12, 2026
Open
$28.33
From 52W high
−25.62%
Volume
375197.00
Market cap
$1.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.6x
P/E (TTM)
3.3x
RSI (14)
49.4
MomentumView details →
1D Return
+1.71%
YTD Return
−14.59%
SummaryUpdated Mar 1, 2026
Galapagos NV (NASDAQ:GLPG) is a Belgian integrated biopharmaceutical company founded in 1999 and headquartered in Mechelen, Belgium. The company went public in 2012 and has evolved from a drug discovery platform into a focused biotechnology company developing innovative therapies for high unmet medical needs. Originally operating across multiple therapeutic areas, Galapagos has undergone significant strategic transformation in recent years, narrowing its focus to oncology and immunology while divesting non-core assets. The company is currently planning a major corporate restructuring that will separate it into two distinct entities by mid-2025.
Similar companies
Latest newsMore news →
Lakefront Biotherapeutics NV repurchased 125,517 of its own shares for about €3.0 million between September 7 and September 11, 2026 under its repurchase program announced on June 9, 2026.5d agoLakefront Biotherapeutics NV repurchased 132,014 of its own shares between August 31 and September 4, 2026, under its buyback program announced on June 9, 2026, for a total of €3,279,463.42.12d agoLakefront Biotherapeutics NV repurchased 127,796 of its own shares between August 24 and August 28, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.19d ago